Results from Research

FHRB Biobank Research 2015-2020

 

2015

Study Title: Personalized Systems Medicine Strategy for Acute Myeloid Leukemia

Principal Investigator: Olli Kallioniemi, Science for Life Laboratory, Karolinska Institutet, Sweden

The objective of this study is to determine how leukemia cells respond to several hundreds of pharmaceuticals in vitro. The leukemia cells are collected from patients with acute myeloid leukemia. The results are then combined with the genetic, transcriptomic and proteomic profiles of the cells. The objective is to improve our understanding of the factors participating in successful response to therapy.

Study Title: Novel molecular markers for disease activity of acute myeloid leukemia

Principal Investigator: Jukka Westermarck, Turku Centre for Biotechnology, University of Turku and Åbo Akademi

The objective of this study is to identify new markers that might predict the response to therapy in patients with acute myeloid leukemia already at the time of diagnosis. The study group is interested in genetic markers, in particular.

Published articles:
Mäkelä et al.: 2019: Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia. Cancers, 11, 1774. https://doi.org/10.3390/cancers11111774

2016

Study Title: Clonal lymphopoiesis in the pathogenesis of bone marrow failure syndromes

Principal Investigator: Satu Mustjoki, Hematology Research Unit Helsinki, University of Helsinki

The objective of this study is to map somatic mutations presenting in the lymphatic cells of patients with aplastic anemia or myelodysplastic syndrome (MDS). The detected mutations are characterized and their functional effects determined. One additional aim is to identify new targets for pharmaceutical agents.

Study Title: Towards curative therapy of Philadelphia chromosome-positive acute lymphoblastic leukemia

Principal Investigator: Satu Mustjoki, Hematology Research Unit Helsinki, University of Helsinki

The objective of this study is to identify novel alternatives for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. An additional objective is to determine the molecular and cell-specific markers predicting good response to tyrosine kinase inhibitors to identify the patients who do not need a stem cell transplant as early as possible.

Published articles:
Hohtari et al 2019: Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. Leukemia. https://doi.org/10.1038/s41375-018-0360-1

Dufva et al 2019: Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity. Blood. https://doi.org/10.1182/blood.2019002121

Study Title: Molecular Genetics and Biology of Myeloproliferative Neoplasms

Principal Investigator: Outi Kilpivaara, Genome-scale biology (GSB) research program, University of Helsinki

The objective of this study is to determine how genetic factors contribute to the development and clinical picture of myeloproliferative diseases (e.g. polycythemia vera, essential thrombocytosis and myelofibrosis). The objective is to improve the diagnostics and treatment of these diseases.

Study Title: Molecular Genetics and Biology of Myeloproliferative Neoplasms

Principal Investigator: Outi Kilpivaara, Genome-scale biology (GSB) research program, University of Helsinki

The objective of this study is to determine how genetic factors contribute to the development and clinical picture of myelodysplastic syndrome and acute myeloid leukemia. The focus of the study is on inherited genetic factors, in particular.

Published articles:
Wartiovaara-Kautto et al 2018: Germline alterations in a consecutive series of acute myeloid leukemia. Leukemia 32;2282-2285. https://doi.org/10.1038/s41375-018-0049-5

Douglas et al 2019: ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2019-01-896233

Study Title: Assessment of the possibilities of molecular medicine in sensitive diagnostics and personalized therapy response evaluation in myelodysplastic syndromes and related myeloid malignancies (MDS-MOLE-2015)

Principal Investigator: Freja Ebeling, Hematology Outpatient Clinic, Helsinki University Hospital (HUS)

The objective of this study is to improve current diagnostics and treatment of myelodysplastic syndrome by studying genetic markers.

Study Title: A systems medicine study to identify novel therapies for blood cancer patients

Principal Investigator: Caroline Heckman, Institute for Molecular Medicine Finland (FIMM), University of Helsinki

The objective of this study is to identify new forms of treatment and response indicators to measure the effects of therapies in leukemias by using drug-sensitivity profiling and exome and RNA sequencing, for example.

2017

Study Title: Assessment of plasma cell content and viability of biobanked multiple myeloma bone marrow samples

Principal Investigator: Caroline Heckman, Institute for Molecular Medicine Finland (FIMM), University of Helsinki

The objective of this study is to assess the quality of bone marrow samples collected from patients with multiple myeloma and stored in a biobank.

Study Title: Integrated platform of novel glycomic and proteomic approaches to investigate structural and functional changes of blood malignancies including: Multiple Myeloma (MM), Acute Myeloid Leukemia (AML) and Amyloidosis.

Principal Investigator: Peter O'Gorman, Mater Misericordiae University Hospital, Ireland

The objective of this study is to determine the progress of leukemias and their response to therapies using glycomic and proteomic approaches for multiple myeloma, acute myeloid leukemia and amyloidosis.

Study Title: Next generation leukemia diagnostics and therapy through p53 isoforms analysis

Principal Investigator: Bjørn Tore Gjertsen, University of Bergen, Norway

The objective of this study is to determine the prevalence of p53 isoforms in primary acute myeloid leukemia, and to assess whether they could be used as diagnostic markers during the course of treatment planning.

2018

Study Title: Genome-wide association study of acute myeloid leukaemia (AML)

Principal Investigator: James Allan, Northern Institute for Cancer Research, Newcastle University, UK

The objective of this study is to identify new alleles associated with acute myeloid leukemia.

Study Title: Improving outcome for patients with Poor Risk Acute Myeloid Leukaemia

Principal Investigator: Jude Fitzgibbon, Barts Cancer Institute, Queen Mary University of London, UK

The objective of this study is to enhance our understanding of the multiple genetic and biochemical factors underlying acute myeloid leukemia with a poor prognosis. The objective is to identify new targets for pharmaceutical agents and markers to identify patients likely to benefit from these drugs.

Study Title: Comprehensive profiling of chronic (CMML) and juvenile (JMML) myelomonocytic leukemia aiming to identify novel targets for treatment

Principal Investigator: Satu Mustjoki, Hematology Research Unit Helsinki, University of Helsinki

The objective of this study is to identify novel methods to treat chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia.

Study Title: Activity of the peptidase enhanced alkylating agent melflufen in light chain amyloidosis and indicators of response

Principal Investigator: Caroline Heckman, Institute for Molecular Medicine Finland (FIMM), University of Helsinki

The objective of this study is to enhance our understanding of the molecular genetic background of light chain amyloidosis and to examine the usability of melflufen in the treatment of this disease.

2019

Study Title: To identify the AML blast population responsible for relapse in FLT3-ITD+/NPM1- AML patients using single cell RNA seq

Principal Investigator: Eva Szegezdi, National University of Ireland, Ireland

The objective of this study is to identify the cell populations participating in the development of relapses in acute myeloid leukemia.

Study Title: Early detection of relapsed AML in children

Principal Investigator: Henrik Hasle, Aarhus University Hospital Skejby, Denmark

The objective of this study is to determine the possibility of follow-up of acute myeloid leukemia in children using patient-specific genetic markers.

Study Title: Drug sensitivity testing and molecular profiling of plasma cell dyscrasias to identify novel treatments and the indicators of response

Principal Investigator: Caroline Heckman, Institute for Molecular Medicine Finland (FIMM), University of Helsinki

The objective of this study is to identify new pharmaceutical agents to treat multiple myeloma, plasma cell leukemia and amyloidosis.

Study Title: The determinants of drug response in acute lymphoblastic leukemia

Principal Investigator: Caroline Heckman, Institute for Molecular Medicine Finland (FIMM), University of Helsinki

The objective of this study is to improve the treatment of acute lymphoblastic leukemia in children and young adults.

2020

Study Title: Acute Myeloid Leukemia Leukemic Initiating Cells: contribution of hypoxia/HIF pathway to chemoresistance and relapse

Principal Investigator: Talia Velasco Hernandez, Josep Carreras Leukaemia Research Institute, Spain

The objective of this study is to analyze the transcriptome by single cell RNA sequencing of the leukemic initiating cells of AML samples of various specific cytogenetic groups.

Published articles:

Study Title: DNA methylation as a biomarker and therapeutic target in T-cell Acute Lymphoblastic Leukemia

Principal Investigator: Riikka Lund and Riina Kaukonen, University of Turku

The aim of this study is to characterize the clonal DNA methylation and the corresponding RNA expression with respect to the drug resistant/responsive phenotypes of individual pediatric, younger adults (19-40 year) and in adults (>40 year) T-ALL patient cells in order to identify DNA methylation biomarkers that could predict therapy outcome.

Published articles:

Study Title: Investigation of the microRNA controlled dysfunctional T cell compartment in the stem cell niche of Myelodysplastic syndrome patients

Principal Investigator: Dagmar Quandt, Institute for Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg, Germany

The objective of this study is to identify differential expressed cell type specific (T cells, progenitor stem cell) microRNA profiles in low-risk and high-risk MDS patients and non-MDS controls and to discover the contribution of the dysregulated T cell compartment to disease onset and progression. The final aim is to propose new therapeutic avenues related to microRNAs and/or T cells for the control of progression from low-risk to high-risk MDS.

Published articles:

Study Title: Immune surveillance and lenalidomide discontinuation in patients with del5q MDS

Principal Investigator: Mikko Myllymäki, Hematology Research Unit Helsinki, University of Helsinki

The objective of this study is to analyze immunophenotypes of del5q myelodysplastic syndrome samples (MSDs) and determine their responses to lenalidomide treatment.

Published articles:

Study Title: Molecular fingerprints for bone marrow cells, MORE

Principal Investigator: Merja Heinäniemi, Institute of Biomedicine, University of Eastern Finland

The overall goal of this study is to harness the full molecular fingerprint of bone marrow cells for accurate identification of clinically relevant cell states.

Published articles:

Study Title: Role of Clever-1 on acute myeloid leukemia (AML)

Principal Investigator: Sirpa Jalkanen, MediCity, University of Turku

The objective of this study is to analyze the effects of immunotherapy Clevegen on AML cell function and viability by utilizing bone marrow collected from AML patients.

Published articles: